TD Asset Management
CRBP icon

TD Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

TD Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,200
Closed -$286K – 1227
2024
Q4 		$286K Sell
24,200
-17,600
-42% -$295K ﹤0.01% 1210
2024
Q3 		$874K Buy
41,800
+1,000
+2% +$51.2K ﹤0.01% 1214
2024
Q2 		$1.85M Buy
40,800
+19,600
+92% +$824K ﹤0.01% 1027
2024
Q1 		$832K Buy
+21,200
New +$523K ﹤0.01% 1207

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TD Asset Management's CRBP Position: Q1 2025 in Review

TD Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 24,200 shares — an estimated $286K sold.

TD Asset Management first reported a position in CRBP in Q1 2024 and held it in 4 quarters. The position peaked at $1.85M in Q2 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • TD Asset Management reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • TD Asset Management sold 24,200 Corbus Pharmaceuticals shares in Q1 2025, an estimated $286K.
  • TD Asset Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • TD Asset Management's Corbus Pharmaceuticals position peaked at $1.85M in Q2 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on TD Asset Management's 13F filing for Q1 2025, filed 7 May 2025.